C07D 239/88
Oxygen atoms
C07D239/88 (Oxygen atoms) appears on 752 US grants and 735 published applications in this corpus.
Search patents in C07D- Granted patents
- 752
- Published applications
- 735
- Assignees
- 443
- Inventors
- 2,635
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 6 | 0 |
| 1977 | 3 | 0 |
| 1978 | 5 | 0 |
| 1979 | 8 | 0 |
| 1980 | 8 | 0 |
| 1981 | 8 | 0 |
| 1982 | 1 | 0 |
| 1983 | 4 | 0 |
| 1984 | 4 | 0 |
| 1985 | 3 | 0 |
| 1986 | 4 | 0 |
| 1987 | 6 | 0 |
| 1988 | 5 | 0 |
| 1989 | 4 | 0 |
| 1990 | 3 | 0 |
| 1991 | 4 | 0 |
| 1992 | 8 | 0 |
| 1993 | 12 | 0 |
| 1994 | 19 | 0 |
| 1995 | 22 | 0 |
| 1996 | 11 | 0 |
| 1997 | 15 | 0 |
| 1998 | 24 | 0 |
| 1999 | 17 | 0 |
| 2000 | 14 | 0 |
| 2001 | 22 | 3 |
| 2002 | 13 | 14 |
| 2003 | 14 | 19 |
| 2004 | 10 | 45 |
| 2005 | 9 | 39 |
| 2006 | 20 | 36 |
| 2007 | 25 | 32 |
| 2008 | 15 | 39 |
| 2009 | 16 | 38 |
| 2010 | 30 | 41 |
| 2011 | 27 | 33 |
| 2012 | 31 | 35 |
| 2013 | 33 | 31 |
| 2014 | 30 | 39 |
| 2015 | 37 | 36 |
| 2016 | 29 | 42 |
| 2017 | 35 | 20 |
| 2018 | 27 | 26 |
| 2019 | 22 | 29 |
| 2020 | 20 | 27 |
| 2021 | 17 | 21 |
| 2022 | 11 | 19 |
| 2023 | 9 | 28 |
| 2024 | 8 | 17 |
| 2025 | 14 | 15 |
| 2026 | 10 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Quinazoline-4(3H)-one derivatives as negative allosteric modulators of metabotropic glutamate receptor 225 Aug 2026US 12,715,879 B2Vanderbilt University
- Crystalline form, and process for its production11 Aug 2026US 12,703,688 B1Alterity Therapeutics Limited
- Heterocyclic compounds as kinase inhibitors for therapeutic uses30 Jun 2026US 12,668,584 B2National Health Research Institutes
- Arylamides and methods of use thereof26 May 2026US 12,637,414 B2Genzyme Corporation
- Histone deacetylase inhibitors26 May 2026US 12,637,433 B2The University of Queensland
- Benzopyrimidin-4(3h)-ones as pi3k inhibitors20 Aug 2026US 2026/0242398 A1OnKure, Inc.
- 3-phenylquinazolinones as novel anti-cancer therapy23 Jul 2026US 2026/0209218 A1Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
- Flavones, quinolinones, quinazolinones, and aurones, and uses in ck2-mediated diseases16 Jul 2026US 2026/0199350 A1The Salk Institute for Biological Studies
- Hsd17b13 inhibitors and uses thereof9 Jul 2026US 2026/0193218 A1Inipharm, Inc.
- Translocator protein ligands and inflammatory diseases25 Jun 2026US 2026/0174761 A1Technion Research & Development Foundation Limited
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta180US 7,932,260 B2ICOS Corporation · 2011
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase171US 5,646,153 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997